First ‐line pembrolizumab for non–small cell lung cancer patients with PD‐L1 ≥50% in a multicenter real‐life cohort: The PEMBREIZH study

ConclusionIn a real ‐life cohort of advanced NSCLC patients (including PS 2 and untreated brain metastases), with PD‐L1 TPS ≥50%, pembrolizumab demonstrates similar PFS to the pivotal clinical trial.

Source: Cancer Medicine - February 6, 2020 Category: Cancer & Oncology Authors: Karim Amrane, Margaux Geier, Romain Corre, Herv é Léna, Guillaume Léveiller, Florence Gadby, Régine Lamy, Jean‐Louis Bizec, Eric Goarant, Gilles Robinet, Sylvie Gouva, Gilles Quere, Ronan Abgral, Ulrike Schick, Cyril Bernier, Christos Tags: ORIGINAL RESEARCH Source Type: research